

ABRF 2019 | ANNUAL MEETING

30 years of challenging the limits of science and technology, opening doors for the future

Sunday
2:30 pm
Rm 214D

The PRG DIA Study: Goals, study design and participation

ABRF Proteomics Research Group

<https://abrf.org/research-group/proteomics-research-group-prg>














Identification of certain commercial equipment, instruments, software or materials does not imply recommendation or endorsement by the National Institute of Standards and Technology, nor does it imply that the products identified are necessarily the best available for the purpose.

Goal of Study

Our goal was to eliminate barriers to adoption and demonstrate where DIA is across platforms and cores.

The Proteomics Research Group

Current members:

- ❖ Pratik Jagtap (Chair)  University of Minnesota
- ❖ Laura Herring  University of North Carolina at Chapel Hill
- ❖ Joanna Kirkpatrick  Leibniz Institute on Aging, Germany
- ❖ LeRoy Martin III  Waters Corporation
- ❖ Mukul Midha  Institute for Systems Biology
- ❖ Benjamin Neely  National Institute of Standards and Technology
- ❖ Brett Phinney  University of California Davis
- ❖ Baozhen (Paul) Shan  Bioinformatics Solutions, Inc.
- ❖ Paul Stemmer  Wayne State University
- ❖ Yan Wang  University of Maryland
- ❖ Allis Chien (EB-liaison)  Stanford University

❖ *Contact prg.abrf@gmail.com*

Goal of Study

Specific Goals

- Provide baseline methods across platforms
- Create and distribute a test sample that can benchmark performance
- Recruit diverse platforms and skill levels
- Collect data with goal of making public
- Analyze data along with industry partners

Intended Benefits of Study

Participant Benefits

- Develop working DIA methods
- Defined sample for self-evaluation
- Use available software to process data
- Compare your work anonymously to others in the area

Community Benefits

- Multi-platform multi-laboratory DIA data on the same sample set
- Anonymous DIA data made publicly available to help algorithm, workflow, and application development and benchmarking
- Serve as demo dataset for newcomers

ABRF Study Timeline

Sample




Blank 25 fmol 100 fmol

HeLa digest spiked with four non-endogenous proteins and iRT

Data Acquisition


- Acquisition parameters were provided
- Total DIA time < 24 h
- Given enough sample to generate library OR spectral library available for download

Software



Participants had the option of using trial licenses from Spectronaut, Scaffold-DIA, and PEAKS DIA

Data analysis & interpretation



- PRG members analyzed data
- Participants encouraged to analyze as well

October
2018

November
2018


December
2018

January
2019

February
2019

March
2019

Spiked proteins



ABRF-1: beta-galactosidase; 1024 aa; 116.5 kDa

ABRF-2: lysozyme C; 147 aa; 16.2 kDa

ABRF-3: glucoamylase; 640 aa; 68.3 kDa

ABRF-4: Protein G; 185 aa; 20.1kDa

Sample A: 25 fmol/ μ g HeLa digest

Sample B: 100 fmol/ μ g HeLa digest


Sample C: blank (just HeLa digest)

Data Acquisition


Data Acquisition

- Acquisition parameters were provided
- Total DIA time < 24 h
- Given enough sample to generate library OR spectral library available for download


- An “adequate” base DIA method
- Attempted a 3.5 sec cycle
- **More on this at 9:30am**



Software and Data Analysis



Participants uploaded data to MassIVE



Participants were eligible for extended licenses to commercial software and non-commercial is always available


Study Participants: 63 labs, 20 countries, 16 US States




Study Participants

- 40 (63%) participants deposited data
- 35 data sets used for prelim analysis
- 53 survey responses (84%)
- Experience was broad
- Majority used provided acquisition method
- Majority of MS platforms were Thermo


LC EXPERIENCE




DIA EXPERIENCE



USED PROVIDED MS METHOD



MS INSTRUMENT



Future Plans and Data Availability

- Continue to look into the nuanced results of the study
- Some trends are consistent within platforms, and that users were consistent across performance metrics
 - if you had “good” DPPP and “good” high protein IDs, then you likely did well at everything else
- Summarize results into manuscripts
- Anonymize raw data and make available before June via MassIVE
- Alert software makers (commercial and non-commercial) to data availability to help with development and education